Several CXCR4 antagonists have been tested using HNSCC cell lines, and the results show that antagonism of CXCR4/CXCR7-CXCL12 downregulates the expression of the chemokines axis and, therefore, could be used to control and potentially even cure nasopharyngeal cancer [8]. Here, CXCR4 is linked to head and neck squamous cell carcinoma.